ALI
4 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19 (NCT05137795) | APR Applied Pharma Research s.a. | 2021-12-15 |
| Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 (NCT04360096) | APR Applied Pharma Research s.a. | 2021-02-15 |
| A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure (NCT04574869) | ReAlta Life Sciences, Inc. | 2021-01-01 |
| Exhaled Breath Particles as a Clinical Indicator for Lung Injury and Acute Respiratory Distress Syndrome (ARDS) (NCT04503057) | Lund University Hospital | 2020-05-01 |
Track ALI automatically
Every clearance here is in the API, with alerts when new ones post.